Document is current
Any future updates will be listed below
-
Authors
Azcue, N. https://orcid.org/0000-0002-6376-4951
Barranco, C.
Tijero-Merino, B. https://orcid.org/0000-0001-9894-5712
Acera, M.
Fernández-Valle, T.
Lafuente, J. V. https://orcid.org/0000-0001-7246-0987
Gabilondo, I. https://orcid.org/0000-0001-6045-2840
Ruiz-Lopez, M.
Del Pino, Rocio https://orcid.org/0000-0002-6612-4757
Gómez-Esteban, J. C. https://orcid.org/0000-0002-4697-3890
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III (PI20/01076)
Osasun Saila, Eusko Jaurlaritzako (2021111006)
Osasun Saila, Eusko Jaurlaritzako (2025333035)
Osasun Saila, Eusko Jaurlaritzako (2022111016)
BIOEF (BIOS21/COV/006)
Ministerio de Ciencia e Innovación (MCIN/AEI/10.13039/501100011033)
Ramón y Cajal Fellowship (RYC2024-049664-I)
Eusko Jaurlaritza (PRE_2024_2_0237)
Ikerbasque, Basque Foundation for Science (Ikerbasque, Basque Foundation for Science)
- License Information
-
More Information
Article History
Received: 1 April 2026
Accepted: 15 May 2026
First Online: 12 June 2026
Declarations
:
: The study protocol was approved by the Basque Drug Research Ethics Committee (Comité de Ética de la Investigación con Medicamentos de Euskadi, CEIm-E; reference PI2020210). All participants provided written informed consent prior to inclusion in the study, in accordance with the Declaration of Helsinki.
: The authors declare that they have no competing interests.
